Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NNVC
NNVC logo

NNVC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy NanoViricides, Inc (NNVC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.720
1 Day change
-0.29%
52 Week Range
2.230
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

NanoViricides, Inc (NNVC) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive catalysts, financial performance is weak, and there are no strong trading signals or analyst support to justify immediate investment.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 63.953, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 1.222 with resistance at 1.416 and support at 1.029.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • NULL identified. No recent news or significant insider/hedge fund activity. The stock has a 70% chance of modest gains (0.47% in the next day, 2.47% in the next week, and 8.75% in the next month).

Neutral/Negative Catalysts

  • Weak financial performance with no revenue growth, declining EPS (-21.43% YoY), and negative net income (-$2,220,719). No recent congress trading data or influential figure activity.

Financial Performance

In Q2 2026, revenue remained at $0 with no growth, net income improved slightly (-9.53% YoY), but EPS dropped significantly (-21.43% YoY). Gross margin is 0, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes. Lack of Wall Street coverage suggests limited institutional interest in the stock.

Wall Street analysts forecast NNVC stock price to rise
1 Analyst Rating
Wall Street analysts forecast NNVC stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.720
sliders
Low
6
Averages
6
High
6
Current: 1.720
sliders
Low
6
Averages
6
High
6
Alliance Global
James Molloy
initiated
$6
AI Analysis
2025-12-16
Reason
Alliance Global
James Molloy
Price Target
$6
AI Analysis
2025-12-16
initiated
Reason
Alliance Global analyst James Molloy initiated coverage of NanoViricides with a Buy rating and $6 price target. NanoViricides is a nano-pharmaceutical company that specializes in creating novel treatments for viral infections, the analyst tells investors in a research note. The firm believes the opportunity for the company "could be significant" should NV-387 show positive data in the planned Phase 2 trials.

People Also Watch